VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ESH CML 2022 | Vodobatinib in patients with CP-CML who have received ≥ 3 prior TKIs including ponatinib

Jorge Cortes, MD, Augusta University, Augusta, GA, gives an update on a Phase I/II study evaluating the safety and efficacy of vodobatinib in patients with chronic phase chronic myeloid leukemia (CP-CML) who have received three or more prior tyrosine kinase inhibitors (TKIs) including ponatinib (NCT02629692). This interview took place at the 24th Annual John Goldman Conference on Chronic Myeloid Leukemia (ESH CML) held in Mandelieu-La Napoule, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Consultant for Pfizer, Novartis, Takeda, Sun Pharma, Rigel and Forma Therapeutics. Dr Cortes’ institution receives research support from Pfizer, Takeda, Novartis and Sun Pharma.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter